Blue Cross and Blue Shield of Kansas (BCBSKS) has published the following updated medical policies on the BCBSKS Website .
Published 10/28/22:

• Genetic and Protein Biomarkers for the Diagnosis and Cancer Risk Assessment of Prostate Cancer
• Germline and Somatic Biomarker Testing (Including Liquid Biopsy) for Targeted Treatment and Immunotherapy in Breast Cancer
• Molecular Analysis for Targeted Therapy or Immunotherapy of Non-Small-Cell Lung Cancer
• Somatic Biomarker Testing (Including Liquid Biopsy) for Targeted Treatment and Immunotherapy in Metastatic Colorectal Cancer (KRAS, NRAF, BRAF, MMR/MSI, HER2, and TMB)

Source: https://www.bcbsks.com/providers/medical-policies